Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 7, 2013, Pages

  Wardrop, Douglas ^a   Estcourt, Lise J ^b   Brunskill, Susan J ^b   Doree, Carolyn ^b   Trivella, Marialena ^c   Stanworth, Simon ^b   Murphy, Michael F ^b  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; LYSINE DERIVATIVE; PLACEBO; TRANEXAMIC ACID; LYSINE; DRUG DERIVATIVE;

BLEEDING; CLINICAL OUTCOME; CONSOLIDATION CHEMOTHERAPY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; EVIDENCE BASED MEDICINE; HEMATOLOGIC DISEASE; HIGH RISK PATIENT; HUMAN; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SCORING SYSTEM; SYSTEMATIC REVIEW; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOEMBOLISM; ANALOGS AND DERIVATIVES; COMPLICATION; HEMATOLOGIC DISEASES; HEMORRHAGE; META ANALYSIS; UTILIZATION; UTILIZATION REVIEW;

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENTS; ERYTHROCYTE TRANSFUSION; HEMATOLOGIC DISEASES; HEMORRHAGE; HUMANS; LYSINE; PLATELET TRANSFUSION; THROMBOCYTOPENIA; TRANEXAMIC ACID;

EID: 84891656109     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009733.pub2     Document Type: Review

References (72)

1. Avvisati G, ten Cate JW, Buller HR, Mandelli F. Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet 1989;2(8655):122-4.
2. Fricke W, Alling D, Kimble J, Griffith P, Klein H. Lack of efficacy of tranexamic acid in thrombocytopenic bleeding. Transfusion 1991;31(4):345-8.
3. Gallardo RL, Gardner FH. Antifibrinolytic therapy for bleeding control during remission induction for acute leukemia. Blood 1983;62:202a.
4. Shpilberg O, Blumenthal R, Sofer O, Eldor A, Ben-Bassat I. A controlled trial of tranexamic acid (TA) treatment for reduction of bleeding during acute myeloid leukemia (AML) induction and consolidation. Blood 1993;82:547a.
5. Shpilberg O, Blumenthal R, Sofer O, Katz Y, Chetrit A, Ramot B, et al. A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. Leukemia and Lymphoma 1995;19:141-4.
6. Amar D, Grant FM, Zhang H, Boland PJ, Leung DH, Healey JA. Antifibrinolytic therapy and perioperative blood loss in cancer patients undergoing major orthopedic surgery. Anesthesiology 2003;98:337-42.
7. Bartholomew J, Salgia R, Bell W. Control of bleeding in patients with immune and non-immune thrombocytopenia with aminocaproic acid. Archives of Internal Medicine 1989;149:1959-61.
8. Bates JS, Buie LW, Woodis CB. Management of menorrhagia associated with chemotherapy-induced thrombocytopenia in women with hematologic malignancy. Pharmacotherapy 2011;11:1092-110.
9. Bedirhan MA, Turna A, Yagan N, Tasci O. Aprotinin reduces postoperative bleeding and the need for blood products in thoracic surgery: results of a randomized double-blind study. European Journal of Cardio-thoracic Surgery 2001;20:1122-7.
10. Ben-Bassat I, Douer D, Ramot B. Tranexamic acid therapy in acute myeloid leukemia: possible reduction of platelet transfusions. European Journal of Haematology 1990;45:86-9.
11. Breen KA, Grimwade D, Hunt BJ. The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia. British Journal of Haematology 2011;156:24-36.
12. Brown SA, Aledort LM, Lee CA. Haemostasis: from bench to bedside. Haemophilia 2002;8:685-93.
13. Byams VR, Dowling NF, Heit JA, Kouides PA, Philipp CS, Stein SF, et al. Quality of life (QOL) evaluation in women with menorrhagia and abnormal hemostasis testing participating in a cross-over study of intranasal desmopressin and oral tranexamic acid. Journal of Thrombosis and Hemostasis 2007;5(2):P-S-189.
14. Cattan A, Schwarzenberg L, Schneider M, Amiel J-L, Mathé G. Trial of epsilon-amino-caproic acid in patients with a bleeding disorder, in particular thrombocytopenic disorders [Essai de traitement par l'acide epsilon-amino-caproique de patients atteints de syndrome hémorragiques, en particulier de syndromes liés a une thrombocytopénie]. La Presse Medicale 1963;71(43):2037-8.
15. Celebi N, Celebioglu B, Selcuk M, Canbay O, Karagoz AH, Aypar U. The role of antifibrinolytic agents in gynecologic cancer surgery. Saudi Medical Journal 2006;27(5):637-41.
16. Chakrabarti S. Low dose bolus aminocaproic acid: an alternative to platelet transfusion in thrombocytopenia. European Journal of Haematology 1998;60:313-4.
17. Dean A, Tuffin P. Fibrinolytic inhibitors for cancer-associated bleeding problems. Journal of Pain and Symptom Management 1997;3(1):20-4.
18. Fossa SD, Solheim OO, Fossa JJ. Cyklokapron (tranexamic acid) in the treatment of patients with advanced neoplasms. Tsdssk Nor Laegeforen 1978;98(28):1368-70.
19. Gardner FH, Helmer RE. Aminocaproic acid: use in control of hemorrhage in patients with amegakaryocytic thrombocytopenia. JAMA 1980;243(1):35-7.
20. Garewal HS, Durie BGM. Anti-fibrinolytic therapy with aminocaproic acid for the control of bleeding in thrombocytopenic patients. Scandinavian Journal of Haematology 1985;35:497-500.
21. Jeserschek R, Clar H, Aigner C, Rehak P, Primus B, Windhager R. Reduction of blood loss using high-dose aprotinin in major orthopaedic surgery. Journal of Bone and Joint Surgery 2003;85(2):174-7.
22. Kalmadi S, Tiu R, Lowe C, Jin T, Kalaycio M. Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage. Cancer 2006;107(1):136-40.
23. Katzel R, Keuper H, Wiedemann B, Brethner L, Viogt B. The effects of intraoperative aprotinin on perioperative haemostasis and fibrinolysis and their effects on blood loss and transfusion requirements in lung surgery [Effekte der intraoperativen Aprotininapplikation auf perioperative Haemostase und Fibrinolyseveraenderungen und ihre Auswirkungen auf Blutverlust und Transfusionsbedarf bei lungenchirurgischen Eingriffen]. Infusionstherapie und Transfusionsmedizin 1998;25:236-45.
24. Levy JH. Novel concepts in treatment and prevention of bleeding. IARS Review Course Lectures. International Anesthesia Research Society, 2005:43-7.
25. Marti-Carvajal AJ, Simancas D, Cardona AF. Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia. Cochrane Database of Systematic Reviews 2011, Issue 6. [DOI: 10.1002/14651858.CD008562.pub2]
26. McConnell JS, Shewale S, Munro NA, Shah K, Deakin AH, Kinninmonth AWG. Reduction of blood loss in primary hip arthroplasty with tranexamic acid or fibrin spray. Acta Orthopaedica 2011;82(6):660-3.
27. McConnell JS, Shewale S, Munro NA, Shah K, Deakin AH, Kinninmonth AWG. Reducing blood loss in primary knee arthroplasty: a prospective randomised controlled trial of tranexamic acid and fibrin spray. Knee 2012;19(4):295-8.
28. Mevio E, Santarelli P. Tranexamic acid in prevention of oropharyngeal radiomucositis [L'acido tranexamico nella prevenzione delle radiomucositi a livello oro-faringeo]. La Radiologia Medica 1983;69:325-8.
29. Movafegh A, Eslamian L, Dorabadi A. Effects of intravenous tranexamic acid administration on blood loss during and after cesarian delivery. International Journal of Gynecology and Obstetrics 2011;115:224-6.
30. Rickles FR, Falanga A, Montesinos P, Sanz MA, Brenner B, Barbui T. Bleeding and thrombosis in acute leukemia: what does the future of therapy look like?. Thrombosis Research 2007;120(2):99-106.
31. Sanz MA, Montesinos P. Open issues on bleeding and thrombosis in acute promyelocytic leukemia. Thrombosis Research 2010;125(2):51-4.
32. Schwartz BS, Williams EC, Conlan MG, Mosher DF. Epsilon-aminocaproic acid in the treatment of patients with acute promyelocytic leukaemia and acquired alpha-2-plasmin inhibitor deficiency. Annals of Internal Medicine 1986;105:873-7.
33. Wassenaar T, Black J, Kahl B, Schwartz B, Longo W, Mosher D, et al. Acute promyelocytic leukemia and acquired alpha-2-plasmin inhibitor deficiency: a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patients. Hematological Oncology 2008;26:241-6.
34. Yang H, Zheng S, Shi C. Clinical study on the efficacy of tranexamic acid in reducing postpartum blood loss: a randomized, comparative, multicenter trial. Chinese Journal of Obstetrics and Gynecology 2001;36(10):590-2.
35. British Committee for Standards in Haematology. Guidelines for the use of platelet transfusions. British Journal of Haematology 2003;122(1):10-23.
36. Bolton-Maggs PHB (editor) and Cohen H on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2011 Annual SHOT Report. Serious Hazards of Transfusion (SHOT), 2012.
37. Cameron B, Rock G, Olberg B, Neurath D. Evaluation of platelet transfusion triggers in a tertiary-care hospital. Transfusion 2007;47(2):206-11.
38. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
39. Faught C, Wells P, Fergusson D, Laupacis A. Adverse effects of methods for minimizing perioperative allogeneic transfusion: a critical review of the literature. Transfusion Medicine Reviews 1998;12(3):206-25.
40. Fergusson DA, Hebert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. New England Journal of Medicine 2008;358(22):2319-31.
41. Franchini M, Dario Di Minno MN, Coppola A. Disseminated intravascular coagulation in hematologic malignancies. Seminars in Thrombosis and Haemostasis 2010;36(4):388-403.
42. Friedmann AM, Sengul H, Lehmann H, Schwartz C, Goodman S. Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients? A reevaluation of prophylactic platelet transfusions. Transfusion Medicine Reviews 2002;16(1):34-45.
43. Greeno E, McCullough J, Weisdorf D. Platelet utilisation and the transfusion trigger: a prospective analysis. Transfusion 2007;72(2):201-5.
44. Guerriero C, Cairns J, Perel P, Shakur H, Roberts I. Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the CRASH-2 trial. PLoS One 2011;6(5):e18987.
45. Gurusamy KS, Pissanou T, Pikhart H, Vaughan J, Burroughs AK, Davidson BR. Methods to decrease blood loss and transfusion requirements for liver transplantation. Cochrane Database of Systematic Reviews 2011, Issue 12. [DOI: 10.1002/14651858.CD009052.pub2]
46. Heddle NM, Webbert K. Chapter 6: Investigation of acute transfusion reactions. In: Murphy MF, Pamphilion DH editor(s). Practical Transfusion Medicine. 3rd Edition. Blackwell, 2009:63-89.
47. Henry DA, Carless PA, Moxey AJ, O'Connell D, Stokes BJ, Fergusson DA, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database of Systematic Reviews 2011, Issue 3. [DOI: 10.1002/14651858.CD001886.pub4]
48. Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
49. Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in Statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
50. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
51. Ker K, Edwards P, Perel P, Shakur H, Roberts I. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ 2012;344:e3054. [PUBMED: 22611164]
52. Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH. Thromboembolism in hospitalized neutropenic cancer patients. Journal of Clinical Oncology 2006;24(3):484-90.
53. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
54. Llewelyn CA, Wells AW, Amin M, Casbard A, Johnson A J, Ballard S, et al. The EASTR study: a new approach to determine the reasons for transfusion in epidemiological studies. Transfusion Medicine 2009;19(2):89-98.
55. Lozano M, Sweeney JD. Avoiding platelet transfusions. In: Sweeney J, Lozano M editor(s). Platelet Transfusion Therapy. Bethesda, Maryland: AABB Press, 2013:567-89.
56. Martin K, Gertler R, Sterner A, MacGuill M, Schreiber C, Horer J, et al. Comparison of blood-sparing efficacy of epsilon-aminocaproic acid and tranexamic acid in newborns undergoing cardiac surgery. The Thoracic and Cardiovascular Surgeon 2011;59(5):276-80.
57. Martin-Hirsch PPL, Keep SL, Bryant A. Interventions for preventing blood loss during the treatment of cervical intraepithelial neoplasia. Cochrane Database of Systematic Reviews 2010, Issue 6. [DOI: 10.1002/14651858.CD001421.pub2]
58. Novikova N, Hofmeyr GJ. Tranexamic acid for preventing postpartum haemorrhage. Cochrane Database of Systematic Reviews 2010, Issue 7. [DOI: 10.1002/14651858.CD007872.pub2]
59. Okamoto S, Hijikata-Okunomiya A, Wanaka K, Okada Y, Okamoto U. Enzyme-controlling medicines: introduction. Seminars in Thrombosis and Hemostasis 1997;23(6):493-501.
60. Pendry K, Davies T. An audit of the use and wastage in the North West of England and North Wales - where have all the platelets gone?. Blood and Transfusion Matters 2011;34:17-9.
61. Pogue JM, Yusuf S. Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis. Controlled Clinical Trials 1997;18(6):580-93.
62. Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion 1985;25(6):573-7.
63. Prentice CR. Basis of antifibrinolytic therapy. Journal of Clinical Pathology Supplement 1980;14:35-40.
64. Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, Dewan Y, et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet 2011;377(9771):1096-101, 1101.e1-2.
65. Roos YB, Rinkel GJE, Vermeulen M, Algra A, van Gijn J. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database of Systematic Reviews 2003, Issue 2. [DOI: 10.1002/14651858.CD001245]
66. Sawamura A, Hayakawa M, Gando S, Kubota N, Sugano M, Wada T, et al. Disseminated intravascular coagulation with a fibrinolytic phenotype at an early phase of trauma predicts mortality. Thrombosis Research 2009;124(5):608-13.
67. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
68. Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010;376(9734):23-32.
69. Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao KJ, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005;105(10):4106-14.
70. Slichter SJ, Kaufman RM, Assmann SF, McCullough J, Triulzi DJ, Strauss RG, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. New England Journal of Medicine 2010;362(7):600-13.
71. Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
72. Tzortzopoulou A, Cepeda MS, Schumann R, Carr DB. Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD006883.pub2]